Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.
Therini Bio has raised $39.0M in total funding. The most recent round was Series A. The last funding was announced in May 2025.
Therini Bio's investors include Eli Lilly, SV Health Investors, Apollo Health Ventures, National Institutes of Health, MRL Ventures Fund.
Therini Bio is headquartered in San Francisco, United States.
Therini Bio specializes in fibrin-targeting therapies to treat inflammatory neurological and retinal diseases.
Therini Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Therini Bio — Funding & Investors." VCBacked, May 14, 2025, https://www.vcbacked.co/company/therini-bio. Accessed July 19, 2026.
VCBacked. (2025). Therini Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/therini-bio
{{cite web |title=Therini Bio — Funding & Investors |url=https://www.vcbacked.co/company/therini-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated